According to a report in a Chinese newspaper, China is planning to spend more than CNY 10 billion (US$1.5 billion) to support the development of new drugs between 2011 and 2016. Biotechnology was identified as one of seven emerging industries that China will use to spearhead the next big step in its economic development.
China set to give a big boost to biologics
Home/Policies & Legislation | Posted 24/09/2010 0 Post your comment
“The development plan for the industries has been submitted to the National Development and Reform Commission and may be announced as soon as the end of this month”, the newspaper reported.
This is not the first time China has stepped in to boost its biotechnology industry. Back in March 2009 the Chinese government announced plans to spend at least CNY 62.8 billion (US$9.2 billion) by the end of 2010 on 11 national research programmes (including biotechnology) to achieve breakthroughs in key technology development.
China is continuing to be attractive as a place to outsource active pharmaceutical ingredients (APIs). Boehringer Ingelheim is the latest in a line of Big Pharma to open a centre in China in order to optimise API and chemical intermediates sourcing.
However, how long China’s appeal will last as reduced tax rebates, correction of the currency rate and increasing wages chip away at China’s cost advantage remains to be seen.
Related article
Is China set to lose its low-cost appeal?
References
21cbh.com [homepage on Internet]. [Accessed 2010 September 9].
China to invest billions on key technology development, bio industry.
National Development and Reform Commission (NDRC). People’s Republic of China [homepage on Internet]. [Accessed 2010 September 9].
Guidelines
New decree for the prescription and commercialization of medicines in Argentina
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
Reports
Follow-on biological/biosimilar approvals in Latin America by therapeutic class
Follow-on biological/biosimilar approvals landscape in Latin America
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Panama enacts new bill to guarantees the supply of medicines
EMA concept paper towards a tailored clinical approach in biosimilar development
Public consultation for the modification of the biosimilars regulation in Brazil
Comments (0)
Post your comment